Want to see SE:QLINEA full AI Analyst Report?
QLINEA Stock Chart & Stats
kr16.50
-kr0.25(-1.52%)
At close: 4:00 PM EDT
kr16.50
-kr0.25(-1.52%)
Day’s Range― - ―
52-Week Rangekr14.55 - kr50.05
Previous CloseN/A
Volume661.00
Average Volume (3M)13.43K
Market Cap
kr341.08M
Enterprise Valuekr147.98
Total Cash (Recent Filing)kr186.77M
Total Debt (Recent Filing)kr11.68M
Price to Earnings (P/E)―
Beta2.74
Next Earnings
Oct 30, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-13.20
Shares Outstanding18,949,081
10 Day Avg. Volume10,725
30 Day Avg. Volume13,430
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.49
Price to Sales (P/S)14.97
P/FCF Ratio-0.98
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-5.51
Revenue Forecast (FY)kr76.80M
Bulls Say, Bears Say
Bulls Say
Low Leverage / Positive EquityVery low reported debt (debt-to-equity ~0.01) and currently positive equity give the company financial flexibility over the next several months. This reduces immediate bankruptcy risk, eases ability to negotiate partnerships or vendor terms, and supports funding product rollouts or placements without heavy interest burdens.
Recurring Consumables-driven Business ModelThe platform-plus-consumables model creates a durable, scalable revenue stream: once instruments are placed, recurring cartridge and reagent sales can grow with installed base. This supports predictable unit economics over time, provides high-margin recurring revenue potential, and aligns incentives for market expansion and service contracts.
Product Focus Aligned With Structural Clinical NeedsConcentrating on rapid ID and AST for severe infections addresses enduring clinical priorities—faster treatment decisions and antibiotic stewardship. Structural demand from hospitals and clinical labs for quicker, actionable AST supports long-term adoption potential and creates a defensible niche versus general diagnostics over the coming months and years.
Bears Say
Substantial Cash Burn And Negative Operating Cash FlowOperating cash outflows of roughly -137M TTM and free cash flow of -111.7M indicate persistent cash burn that will pressure runway absent financing or rapid revenue scaling. Continued negative cash generation constrains R&D and commercialization spending, increases dilution risk from capital raises, and complicates multi-quarter planning.
Deep, Sustained Negative Margins And LossesConsistently negative gross, operating, and net margins show the business has not reached a viable cost structure. Large cumulative losses (TTM ~-152.6M) imply the company must materially improve pricing, throughput, cost per test, or scale consumables rapidly to achieve sustainable profitability, a multi-quarter operational challenge.
Small, Volatile Revenue BaseTTM revenue near $9.9M with low and volatile growth limits the firm's ability to absorb fixed costs and fund commercial scale-up. A small installed base slows recurring consumables growth and makes margin improvements sensitive to single large contracts, meaning sustainable scale and predictable cash generation remain uncertain in the near-to-medium term.
Q-linea AB News
QLINEA FAQ
What was Q-linea AB’s price range in the past 12 months?
Q-linea AB lowest stock price was kr14.55 and its highest was kr50.05 in the past 12 months.
What is Q-linea AB’s market cap?
Q-linea AB’s market cap is kr341.08M.
When is Q-linea AB’s upcoming earnings report date?
Q-linea AB’s upcoming earnings report date is Oct 30, 2026 which is in 75 days.
How were Q-linea AB’s earnings last quarter?
Q-linea AB released its earnings results on Jul 10, 2026. The company reported -kr1.58 earnings per share for the quarter, missing the consensus estimate of N/A by -kr1.58.
Is Q-linea AB overvalued?
According to Wall Street analysts Q-linea AB’s price is currently Overvalued.
Does Q-linea AB pay dividends?
Q-linea AB does not currently pay dividends.
What is Q-linea AB’s EPS estimate?
Q-linea AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Q-linea AB have?
Q-linea AB has 18,949,081 shares outstanding.
What happened to Q-linea AB’s price movement after its last earnings report?
Q-linea AB reported an EPS of -kr1.58 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 7.453%.
Which hedge fund is a major shareholder of Q-linea AB?
Currently, no hedge funds are holding shares in SE:QLINEA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Q-linea AB
Q-linea AB (publ), founded in 2008 and based in Uppsala, Sweden, specializes in developing diagnostic instruments and associated consumables for infection detection. The company crafts advanced in vitro diagnostic platforms, specifically engineered to identify infectious diseases. A key product is ASTar, an innovative system designed to rapidly assess antibiotic susceptibility in positive blood cultures. Q-linea's overarching mission is to deliver cutting-edge solutions to healthcare professionals.
Technical Analysis
Vicore Pharma Holding AB
―
Isofol Medical AB
―
Biovica International AB Class B
―
Doxa AB
―
Guard Therapeutics International AB
―